Resolution on (A) amendment of the Articles of Association; (B) decrease of the share capital to cover loss; and (C) decrease of the share capital for allocation to unrestricted shareholders' equity

The board of directors of Alligator Bioscience AB, Reg. No. 556597-8201, proposes that the extraordinary general meeting on 26 August 2026 resolves on (A) amendment of the Articles of Association; (B) decrease of the share capital to cover loss according to what is set out below; and (C) decrease of the share capital for allocation to unrestricted shareholders' equity, in accordance with what is set out below.

A. Amendment of the Articles of Association

The board of directors proposes that the meeting resolves to amend the company's Articles of Association in accordance with the following:

§ 4 Share capital

Current wording
The share capital of the company shall be no less than SEK 60,000,000 and no more than SEK 240,000,000.

Proposed wording
The share capital of the company shall be no less than SEK 3,000,000 and no more than SEK 12,000,000.

B. Decrease of the share capital to cover loss

The board of directors proposes that the meeting resolves to decrease the share capital with SEK 112,379,938.92 to cover loss and without the redemption of shares. The decrease decreases the share capital from SEK 125,621,369.60 to SEK 13,241,430.68, whereby the share's quota value decreases from SEK 0.20 to approximately SEK 0.02.

C. Decrease of the share capital for allocation to unrestricted shareholders' equity

The board of directors further proposes that the extraordinary general meeting resolves to decrease the share capital by an additional SEK 10,100,896.44 for allocation to unrestricted shareholders' equity, without the redemption of shares. The reason for the board of directors' proposal to decrease the company's share capital under this item C is to improve the ratio between the share capital and unrestricted equity.

As a statement pursuant to Chapter 20, Section 13 of the Swedish Companies Act (2005:551), the board of directors may state the following. The resolution to decrease the company's share capital in accordance with the proposal in this item C may be implemented without authorization from the Swedish Companies Registration Office or a general court, since the company will simultaneously carry out a rights offering of units, which means that neither the company's restricted equity nor its share capital, will be decreased. The board of directors' proposed resolution to approve the board of director's resolution regarding the rights of units is set forth in item 8 on the agenda for the meeting.

Following the reduction of the share capital in accordance with item B above, the effect of the board of director's proposal regarding the reduction of the share capital under this item C will be that the share capital and restricted equity will decrease by SEK 10,100,896.44 to SEK 3,140,534.24, whereby the quota value of the share will simultaneously decrease from approximately SEK 0.02 to SEK 0.005. If the rights issue is fully subscribed, the share capital and restricted equity will subsequently increase by SEK 31,405,342.40 (based on the new quota value) to SEK 34,545,876.64. If the rights issue is subscribed to only the guaranteed level (approximately 47 percent), the share capital and restricted equity will increase by SEK 14,700,000.00 to SEK 17,840,534.24.

The board of directors' proposals under A–C above constitutes a joint proposal and shall be resolved upon as a joint resolution.

The resolution is conditional upon the meeting also resolving in accordance with items 7–10 in the notice.

For a valid resolution, the proposal must be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the meeting.

The company's CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office (*Sw*. Bolagsverket).

Lund on 23 July 2026

The Board of Directors of Alligator Bioscience AB (publ)